Get started
SANOFI S.A.SS

SANOFI S.A.

100.304CHFR
+1.034+1.04%
Last update at Mar 3, 11:20 GMT
CHF
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Bonds

SNW fundamentals

Key facts

Market capitalization‪131.22 B‬CHF
Dividend yield (indicated)3.60%
Price to earnings Ratio (TTM)23.85
Basic EPS (TTM)4.18CHF
Founded1994
Employees (FY)‪84.59 K‬
CEOPaul Hudson
Websitesanofi.com
About

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Ownership
‪‪1.25 B‬‬
Free Float shares
‪‪1.15 B‬‬ (91.69%)
Closely held shares
‪‪104.12 M‬‬ (8.31%)
Free Float shares
‪‪1.15 B‬‬ (91.69%)
Closely held shares
‪‪104.12 M‬‬ (8.31%)
Capital structure
Market cap
‪‪131.22 B‬‬
Debt
‪‪16.83 B‬‬
Minority interest
‪‪329.07 M‬‬
Cash & equivalents
‪‪7.10 B‬‬
Enterprise value
‪‪141.28 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪131.22 B‬‬
Price to earning ratio (P/E)
23.85x
Price to sales ratio (P/S)
3.23x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
23.85x
Price to sales ratio (P/S)
3.23x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪7.00‬
‪14.00‬
‪21.00‬
‪28.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪8.5%‬
‪12.5%‬
‪16.5%‬
‪20.5%‬
‪24.5%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
‪‪24.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
‪‪20.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
‪‪20.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Biopharma
By country
Period: 2024
United States
Other Countries
Europe
France

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2021
2022
2023
2024
2025
‪0.00‬
‪‪12.00 B‬‬
‪‪24.00 B‬‬
‪‪36.00 B‬‬
‪‪48.00 B‬‬
Actual
Estimate
Earnings
Next:—
H2 '22
H2 '23
H1 '24
H2 '24
‪0.00‬
‪1.20‬
‪2.40‬
‪3.60‬
‪4.80‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
88.23%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
3.46%
Last payment
3.686
Last ex-date
May 13, 2024
Dividend history
‪3.5%‬
‪3.7%‬
‪3.9%‬
‪4.1%‬
‪4.3%‬
2020
2021
2022
2023
2024
‪0.00‬
‪1.00‬
‪2.00‬
‪3.00‬
‪4.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−8.00 B‬‬
‪0.00‬
‪‪8.00 B‬‬
‪‪16.00 B‬‬
‪‪24.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪25.00 B‬‬
‪‪50.00 B‬‬
‪‪75.00 B‬‬
‪‪100.00 B‬‬
Assets
Liabilities